Delcath Systems (NASDAQ:DCTH) & INVO Bioscience (NASDAQ:INVO) Head-To-Head Review

INVO Bioscience (NASDAQ:INVO) and Delcath Systems (NASDAQ:DCTH) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, valuation, institutional ownership, dividends, analyst recommendations, risk and earnings.

Valuation and Earnings

This table compares INVO Bioscience and Delcath Systems”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
INVO Bioscience	$5.77 million	0.83	-$8.03 million	N/A	N/A
Delcath Systems	$37.21 million	13.25	-$26.39 million	($0.50)	-28.32

INVO Bioscience has higher earnings, but lower revenue than Delcath Systems.

Analyst Recommendations

This is a summary of current ratings and target prices for INVO Bioscience and Delcath Systems, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
INVO Bioscience	0	0	0	0	0.00
Delcath Systems	0	0	4	0	3.00

Delcath Systems has a consensus target price of $24.00, suggesting a potential upside of 69.49%. Given Delcath Systems’ stronger consensus rating and higher probable upside, analysts clearly believe Delcath Systems is more favorable than INVO Bioscience.

Risk & Volatility

INVO Bioscience has a beta of 1.43, indicating that its stock price is 43% more volatile than the S&P 500. Comparatively, Delcath Systems has a beta of 0.95, indicating that its stock price is 5% less volatile than the S&P 500.

Insider & Institutional Ownership

12.0% of INVO Bioscience shares are owned by institutional investors. Comparatively, 61.1% of Delcath Systems shares are owned by institutional investors. 3.5% of INVO Bioscience shares are owned by company insiders. Comparatively, 17.4% of Delcath Systems shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares INVO Bioscience and Delcath Systems’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
INVO Bioscience	-122.79%	N/A	-36.94%
Delcath Systems	-26.38%	-29.44%	-20.75%

Summary

Delcath Systems beats INVO Bioscience on 9 of the 12 factors compared between the two stocks.

About INVO Bioscience

INVO Bioscience, Inc., together with its subsidiary, a healthcare services fertility company, provides assisted reproductive technology solutions worldwide. It offers INVOcell, a medical device that allows fertilization and early embryo development to take place in vivo within the woman’s body. The company was founded in 2007 and is based in Sarasota, Florida.

About Delcath Systems

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.